Vitamin C Depigmenattion Versus Conventional Technique
Launched by CAIRO UNIVERSITY · Oct 23, 2018
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
In addition to all of the previously mentioned actions of vitamin C, it was found to be involved in depigmentation due to several factors that not only depend on its direct effect on melanin and melanocytes but also due to the overall effect on the applied tissues. Melanin is one of the main reservoir for ROS, copper and calcium in the tissue cells . Once vitamin C is introduced to the target tissue, it binds efficiently to melanin due to the ROS, calcium and copper content which causes intracellular deficiency of these items and the inability of the cells to produce melanin. Calcium defici...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18-50 y
- • medically free;
- • physiologic gingival hyperpigmentation related to esthetic region were selected.
- Exclusion Criteria:
- All the reasons that could provoke an inflammatory reaction were excluded such as:
- • systemic diseases (especially auto-immune diseases and chemotherapy uptake);
- • pregnant and lactating mothers;
- • usage of chlorhexidine or povidone iodine;
- • Local causes (smoking and periodontitis).
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
nermin yussif
Study Director
msa university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials